The hepatitis C virus is spreading at a faster rate among Americans than HIV/AIDS and currently affects approximately 4.1 million people in the U.S.1
Whether you are considering or beginning PEGINTRON® treatment, use this page to hear how other people have successfully managed treatment and beaten hepatitis C. Hearing real life stories like the ones told by Jackie, a 41-year-old nurse, or Jim, a 58-year-old jazz musician, can help you to learn about living with hepatitis C and what's involved with treatment.
Sustained Viral Response (SVR) was achieved by 44.2% of all patients receiving PEGINTRON®/REBETOLPEGINTRON®/REBETOL® Capsules combination therapy. Of these patients, end-of treatment response was 59.2%, with a 15.3% relapse rate.2 See below for Important Safety Information and Prescribing Information.
The people presented here are real patients who have successfully completed PEGINTRON®/REBETOL® (Ribavirin, USP) Capsules combination therapy. They have agreed to allow Schering Corporation to use their photographs and stories on this Web site. No compensation has been given to any of these individuals.
1 Armstrong, G. L., Wasley, A., Simard, E.P., et al. The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002. Annals of Internal Medicine. 16 May, 2006. 144: 705-714. Available at: http://www.annals.org/cgi/content/full/144/10/705. Accessed January 14, 2009.
2 Ira M. Jacobson IM, Brown Jr. RS, Freilich B. et al. Peginterferon alfa-2b and Weight-Based or Flat-Dose Ribavirin in Chronic Hepatitis C Patients: A Randomized Trial. Hepatology. October, 2007. 46(4): 971-981. Available at http://www3.interscience.wiley.com/cgi-bin/fulltext/116323744/PDFSTART. Accessed February 3, 2009
